AMLX
Price
$18.41
Change
+$0.82 (+4.66%)
Updated
Jul 24 closing price
Capitalization
2.05B
11 days until earnings call
Intraday BUY SELL Signals
RGNX
Price
$9.73
Change
-$0.52 (-5.07%)
Updated
Jul 24 closing price
Capitalization
622.92M
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs RGNX

AMLX vs RGNX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMLX vs. RGNX commentary
Jul 26, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and RGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2026
Stock price -- (AMLX: $18.41 vs. RGNX: $9.73)
Brand notoriety: AMLX and RGNX are both not notable
AMLX represents the Pharmaceuticals: Generic, while RGNX is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 73% vs. RGNX: 27%
Market capitalization -- AMLX: $2.05B vs. RGNX: $622.92M
AMLX [@Pharmaceuticals: Generic] is valued at $2.05B. RGNX’s [@Biotechnology] market capitalization is $622.92M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $121.16B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.01B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, AMLX is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 6 TA indicator(s) are bullish while RGNX’s TA Score has 5 bullish TA indicator(s).

  • AMLX’s TA Score: 6 bullish, 4 bearish.
  • RGNX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, AMLX is a better buy in the short-term than RGNX.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а +3.72% price change this week, while RGNX (@Biotechnology) price change was -1.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.31%. For the same industry, the average monthly price growth was -3.61%, and the average quarterly price growth was +12.04%.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.

Reported Earning Dates

AMLX is expected to report earnings on Aug 06, 2026.

RGNX is expected to report earnings on Aug 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.31% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-4.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($2.05B) has a higher market cap than RGNX($623M). AMLX YTD gains are higher at: 52.401 vs. RGNX (-32.431). AMLX has higher annual earnings (EBITDA): -158.8M vs. RGNX (-229.35M). AMLX has more cash in the bank: 280M vs. RGNX (150M). AMLX has less debt than RGNX: AMLX (5.63M) vs RGNX (71.1M). RGNX has higher revenues than AMLX: RGNX (87.8M) vs AMLX (0).
AMLXRGNXAMLX / RGNX
Capitalization2.05B623M329%
EBITDA-158.8M-229.35M69%
Gain YTD52.401-32.431-162%
P/E Ratio2.69N/A-
Revenue087.8M-
Total Cash280M150M187%
Total Debt5.63M71.1M8%
FUNDAMENTALS RATINGS
RGNX: Fundamental Ratings
RGNX
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
58
P/E GROWTH RATING
1..100
25
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXRGNX
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
77%
Momentum
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend about 1 month ago
79%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
RGNX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VEUSX110.590.50
+0.45%
Vanguard European Stock Admiral
GSNPX25.220.10
+0.40%
Goldman Sachs International Eq Inc P
MTINX25.720.06
+0.23%
NYLI Income Builder Investor Class
ABWYX16.750.01
+0.06%
AB All Market Total Return Advisor
ECFGX19.21-0.13
-0.67%
Eaton Vance Focused Growth Opps C

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
+4.66%
OCUL - AMLX
46%
Loosely correlated
-1.33%
LRMR - AMLX
45%
Loosely correlated
-0.25%
JAZZ - AMLX
43%
Loosely correlated
-0.39%
RGNX - AMLX
43%
Loosely correlated
-5.07%
IDYA - AMLX
43%
Loosely correlated
-2.29%
More